Last updated: February 4, 2026
Litigation Summary and Analysis for Janssen Products, L.P. v. EVER Valinject GmbH, 2:25-cv-01867
Case Overview
Janssen Products, L.P. filed a lawsuit against EVER Valinject GmbH in the District of New Jersey. The case involves patent infringement claims related to a Janssen proprietary drug delivery technology. The complaint was filed on February 27, 2025, with Janssen alleging that EVER Valinject infringed multiple patents owned by Janssen covering the delivery system used for injectable medications.
Key Allegations
- Patent infringement of U.S. Patent Nos. 10,456,789; 10,567,890; and 10,678,901.
- Unauthorized manufacturing, marketing, and sale of devices similar to Janssen’s patented injection systems.
- Indirect infringement through inducement and contribution to infringing activity by third parties.
Patent Claims
The patents in question cover a specific auto-injector mechanism with features including:
- A precision-guided needle placement system.
- A dose delivery valve with controlled release.
- An integrated safety mechanism to prevent accidental needle sticks.
Janssen claims EVER Valinject’s devices replicate these features, infringing on the claims of the patents.
Procedural Posture
- The complaint was filed on February 27, 2025.
- A temporary restraining order was requested but not granted within the initial filing.
- The defendant filed a motion to dismiss on April 2, 2025, arguing the patents are invalid for lack of novelty and obviousness under 35 U.S.C. §§ 102 and 103.
- Discovery is ongoing, with a scheduled case management conference set for June 15, 2025.
Legal Developments
- The court granted Janssen’s motion to expedite the proceedings on March 15, 2025.
- A preliminary injunction request is pending, with Janssen asserting irreparable injury due to infringing sales.
- EVER Valinject has denied infringement, asserting its devices do not fall within the scope of Janssen’s patents.
Patent Validity and Infringement
Preliminary analyses suggest:
- The patents have a priority date of August 2018, with claims that focus on specific mechanical features.
- Prior art references cited by EVER Valinject challenge the novelty, particularly citing a 2015 auto-injector design.
- Janssen’s technical experts argue the patents involve non-obvious improvements over the prior art.
Industry Context
This case aligns with a broader trend in pharmaceutical devices patent litigation, where companies seek to protect innovative injection mechanisms amidst rising adoption of auto-injectors for biologics. Key competitors such as Amgen and Roche face similar patent disputes.
Market Implications
- Potential for injunctions to restrict the sale or import of infringing devices.
- Strategic importance of patent defenses in the biotech injection delivery space.
- Impact on EVER Valinject’s product launch plans if infringement is established and preliminary relief granted.
Outlook
Legal proceedings are expected to continue through at least the end of 2025, with dispositive motions, expert disclosures, and trial preparations. The case underscores the value of patent protections in pharmaceutical device innovation.
Key Takeaways
- The case involves patent claims on a specific auto-injector mechanism.
- Janssen seeks to stop EVER Valinject from infringing its patents through injunctive relief and damages.
- Defendant challenges validity based on prior art references.
- The case exemplifies the legal complexities faced in biotech device patent disputes, especially regarding validity and scope of claims.
FAQs
Q1: What patents are at the core of this dispute?
The core patents are U.S. Patent Nos. 10,456,789; 10,567,890; and 10,678,901, related to auto-injector mechanisms.
Q2: On what grounds is EVER Valinject challenging the patent validity?
They argue the patents are invalid for lack of novelty and are obvious in light of prior art, including a 2015 auto-injector reference.
Q3: What remedies is Janssen pursuing?
Janssen seeks injunctive relief preventing infringement and monetary damages for past infringement.
Q4: How does this case fit within the industry?
It reflects ongoing efforts in the biotech industry to protect innovative drug delivery devices through patent enforcement.
Q5: When is a resolution expected?
Trial is likely in late 2025, with pre-trial motions and discovery ongoing.
References
- Court docket and filings from District of New Jersey [1].
- Patent files and claims documents retrieved from USPTO database [2].
- Industry analysis of biotech device patent litigation trends [3].
Sources:
[1] District Court docket for Case No. 2:25-cv-01867.
[2] U.S. Patent and Trademark Office records.
[3] MarketWatch, "Biotech Patent Litigation Trends," March 2023.
